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Introduction 
The epigenetic and genetic reprogramming or 
modifications due to the genomic instability are thought 
to be the fundamental features of tumorigenesis. These 
modifications result in the expression of abnormal or 
mutated proteins. Therefore, the antigenic characteristics 
of the tumor cells can be perceived by the innate and 
cognate immune systems - a phenomenon known 
as immunosurveillance.1 However,  it should be 
pointed out that the cancer cells are able to adopt 
some crucial mechanisms to secure their survival, 
proliferation, progression and invasion even after chemo/
immunotherapy. These strategies may manifest by emerging 
their own growth signals, resisting to growth-inhibitory 
signals, challenging apoptotic processes, preserving their 
replicative potentials, sustaining angiogenesis, and finally, 
migrating by metastatic invasion and colonizing into the 
neighboring tissues and organs.2 In fact, cancer cells are able 
to escape the immunosurveillance functions of immune 
system through immunomodulation, immunoselection/
immunoediting and immunosubversion.3 In addition, 
solid tumors attain unique capability to create a permissive 
milieu – the so-called tumor microenvironment (TME) 
– to escape such immunosurveillance. TME is often 
associated with aberrant metabolisms (e.g., anomalous 
consumption of glucose and L-tryptophan), emergence 
of irregular microvasculature and modified interstitium 
with high pressure fluid that impose significant 
pathophysiologic barrier functions against cancer 
treatment modalities.4,5 Further, within TME, tumor cells 
impose immunosuppressive functions via regulatory T 
(Treg) cells and/or myeloid-derived suppressor cells and 
downregulation of major histocompatibility complex 
(MHC) expression.1,6 The malignant cells, unlike normal 
cells, are able to escape the anoikis7,8 during metastasis, 
while their death can hardly ever induce any immune 
responses against tumor cell derived antigens. 
As one of intriguing mechanisms, cancer cells exploit 
membranous vesicles machineries for communication 
with the neighboring cells. These cellular communication 
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Abstract
Introduction: Exosomes (EXOs) and ectosomes (ECTOs) are 
nanoscale membranous extracellular vesicles (EVs) derived 
from different cells mediating various cellular communications. 
EXOs are liberated based on the exocytosis of multivesicular 
bodies, while ECTOs are ubiquitously released from the plasma 
membranes. 
Methods: Here, in this paper, we go over the extracellular 
vesicular machineries and concisely highlight their clinical 
importance in solid tumors and their possible applications in 
cancer immunotherapy/vaccination.
Results: In various types of cancers, these vesicles play central roles delivering cancer cell messages 
to the target cells, as a result both of them seem to provide a novel useful means for diagnosis and 
therapy of malignancies. Dendritic cell-derived exosomes (DEXOs) are able to activate the tumor 
antigen-specific CD8+ cytotoxic T-lymphocytes (CTLs) and hence induce antitumor responses 
in vivo. Within the tumor microenvironment (TME), however, tumor cells seem to  generate 
exosomes (the so-called oncosoems) that may act in favor of tumor progression. 
Conclusions: As complex systems, these vesicular micro-/nano-machines convey important 
cellular messages dependent upon the cells/tissue setting(s). In addition to their potential in 
diagnosis of cancers, they have been exploited for cancer immunotherapy/vaccination. However, 
such treatment strategies need to be carefully designed to attain desired clinical outcomes. 
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machineries are known as exosomes (EXOs) and 
ectosomes (ECTOs), which are micro-/nano-scaled 
vesicles secreted from various cells to convey messages 
related to immune responses and signal transductions.9 
Biogenesis of extracellular vesicles
The biogenesis of bioactive EXOs commences with the 
fusion of multivesicular bodies (MVBs) with the plasma 
membrane and release of intraluminal vesicles (ILVs) as 
EXOs.10 This phenomenon, which was initially observed 
as a mechanism for the removal of transferrin receptor 
during maturation of reticulocytes, is now considered 
as an alternative secretory pathway of the endocytic 
network; readers are directed to see a previously 
published book chapter on “Biological membranes 
and barriers” for the vesicular trafficking.11 In fact, the 
MVBs are intermediate cellular compartments originated 
from endosomes through invagination of the limiting 
endosomal membrane. The ILVs, which are not yet 
released to the extracellular space, can drive the formation 
of EXOs (50-100 nm in diameter) that are released on 
the exocytosis of MVBs. Unlike EXOs, the ECTOs (50-
350 nm in diameter) are ubiquitous vesicles assembled 
at and released from the plasma membrane.12 The fusion 
of liberated EVs with target cells is initiated through 
interaction of the external faces of cell membranes, which 
is mediated by fusogens such as syncytin-1. Both EXOs 
and ECTOs show rolling and membrane fusion potential 
with rapid dissolution and specific markers such as CD63 
and CD61 for EXOs, and TyA and C1q for ECTOs.12 Fig. 1 
represents schematic illustration of various extracellular 
vesicles in  communication with other cells such as B 
and T lymphocytes and the biogenesis of such vesicular 
machineries. 
EXOs derived from dendritic cells (DCs) are 
known as dexosomes (DEXOs) that contain ligands 
capable of activating the natural killer (NK) cells. 
Immunomodulatory impacts of DEXOs provide 
possibility towards development of reprogramed DEXOs 
for the specific activation of immune system including 
invariant Natural killer T (NKT) cells and antigen-specific 
T and B lymphocytes.13 As shown in Fig. 1 (panel A), 
compelling evidences have shown that tumor antigen-
loaded DEXOs are able to activate the tumor antigen-
specific CD8+ cytotoxic T-lymphocytes (CTLs) and 
hence induce antitumor responses in animal models 
and human clinical trials.14 However, it appaers that 
there exist somewaht controversies upon the impacts 
Fig. 1. Schematic illustration of extracellular vesicles in solid tumors. A) Tumor cells-derived exosomes (TEXOs) and dendritic cells-
derived exosomes (DEXOs) in tumor microenvironment of small intestine cancer. B) Extracellular vesicles (EVs) communication with B 
and T lymphocytes. C) Biogenesis of exosomes (EXOs) and ectosomes (ECTOs) in dendritic cells.
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of the EVs, perhaps becuase of the tumor cells-derived 
exosomes (TEXOs) that is favor of cancer progreesion. 
For the biogenesis of EXOs (Fig. 1C), transmembrane 
proteins should be endocytosed and transferred into the 
early endosomes. While the “endosomal sorting complex 
required for transport” (ESCRT) for the early endosomal 
sorting (ESCRT-0) involves ubiquitinated proteins, 
sorting of the late endosome by intraluminal vesicles 
(ILVs) and forming of the multivesicular bodies (MVBs) 
are mediated by ESCRT-I and –II. Then, as demonstrated 
in Fig. 1 (panels B and C), the formed MVBs can undergo 
either the liberation of ILVs (i.e., through exocytosis of 
EXOs to the extracellular space) or the degradation of 
ILVs (i.e., via fusion of MVBs with lysosomes). 
For the formation of ECTOs (Fig. 1C), transmembrane 
proteins (e.g., tetraspanins, matrix metalloproteinase 
MT1-MMP, integrins, receptor agonists) are assembled 
in distinct membrane domains creating some kind of 
molecular raft – key to outward membrane budding. 
This occurs in association with lipidic anchors (e.g., 
myristoylation, palmitoylation) of proteins, and the Ca2+-
activated scramblases that randomize the distribution of 
lipids. Then, the cytoskeleton becomes limper and various 
cytosolic proteins and RNA molecules are sustained 
within the vesicles. The ECTOs are then pinched off, 
in which TSG101, a member of the ESCRT-I complex, 
mediates mobilization of ESCRT-III towards plasma 
membrane facilitating the assembly of a spiral form 
structure. This structure is disassembled by ATPase VPS4, 
and finally ECTOs are liberated, readers are directed to a 
comprehensive review published recently by Cocucci and 
Meldolesi.12
Clinical impacts of EVs
It should be articulated that the cancer-derived EVs 
encompass biological information and elements (e.g., 
receptors, enzymes, biomarkers, reactive oxygen species, 
genetic markers) as well as a number of key oncogenes 
and RNA molecules that can induce proneoplastic effects. 
The contents of normal and cancer cells-generated EVs 
show marked differences. Large TEXOs (the so-called 
oncosomes) were shown to mediate intercellular transfer 
of distinct classes of functional microRNA, namely, 
enhanced migration of cancer-associated fibroblasts 
(CAFs) by miR-1227. Among the proteins enriched in 
TEXOs, cytokeratin 18 (CK18) was reported as one of the 
most abundant oncomarkers found in the circulation and 
tissues of prostate cancer cases.15 Through secretion of 
TEXOs, the migrating tumor cells happen to condition the 
distant sites to make them permissive for colonizing and 
thereby advancing the disease.16 It should be pointed out 
that cancer-originated EVs display marked ability to elicit a 
rapid tissue growth, while other extracellular vesicles (e.g., 
DEXOs) can impose tumor suppressor potentials. Thus, it 
seems that the vesicular nanomachines, depending on the 
cell origin, are able to shuttle bioelements to the target cells, 
which can either promote or suppress the cancer-related 
phenotypes.12 Of note, TEXOs enriched in patients’ sera 
can be isolated and used as a reliable individual-specific 
source of antigens to load DCs. Such antigen-loaded DCs 
can be exploited as personalized anticancer vaccination 
modality.17
In addition to the cell-based vaccination and 
immunotherapy of cancer using re-programed 
individualized DCs, the DEXOs were shown to provide 
well-tolerated promising modalities for vaccination against 
malignancies.18 Recently, in a phase I/II clinical trial, seven 
patients with advanced stage of squamous cell carcinoma 
of esophagus were treated with a vaccine comprised of 
monocyte-derived dendritic cells (moDCs) pulsed with 
SART1 peptide. It was found that the vaccine was able to 
induce SART1 peptide-specific cytotoxic T lymphocytes 
(CTLs) while the moDCs were able to liberate DEXOs 
capable of inducing SART1 peptide-specific CTLs.19 
However, the efficacy of DEXOs-based immunotherapy 
against cancer depends on the responsiveness of both 
B and T lymphocytes, which is in turn reliant upon the 
presence of both T- and B-cell DEXO-associated epitopes.20 
DEXOs contain various proteins and lipid necessary for 
biological functions of EVs. Among these components, 
immunorelevent molecules such as MHC molecules, 
costimulatory molecules, heat shock proteins (HSP), 
and peptide antigens are responsible for striking role of 
DEXOs in T cell (CD8+ and CD4+ ) dependent anti-tumor 
immune response stimulation. Several studies confirmed 
potential effects of EXOs loaded antigen to eradicate 
tumor in vitro, ex vivo and in vivo, in which addition 
of immune stimulation components (TLRs agonists, 
bacterial/viral peptides) may enhance the immune 
response. For instance, incorporation of the G protein of 
vesicular stomatitis virus into EXOs co-expressed with 
antigen was shown to improve (a) maturation of active 
DCs, (b) stimulation of antigen specific responses of 
CTLs, (c) upregulation of costimulatory molecules (CD80, 
CD86, CD40), (d) generation of IL12 as a DC effector, and 
(e) acceleration of antigen internalization by endocytosis 
following presenting by the MHC class I.21 
Up until now, capitalizing on clinical potential of EVs, 
a number of clinical trials have been settled. The first 
clinical trial study supported by the Institute Gustave 
Roussy in France was performed using autologous EXOs 
pulsed with MAGE 3 peptides for the immunization of 
stage III/IV melanoma patients. In this study, fifteen 
HLA-A1+, B35+, HLA DPO4+ metastatic melanoma 
patients expressing MAGE3 antigen on tumor cells were 
undergone the trail, and the autologous DEXOs pulsed 
with MHC class I-peptide or MHC class II –peptide 
were administered subcutaneously/intradermally in 
different dosages (4 times weekly). No major toxicity was 
observed in patients under such immunization modality. 
The results showed that, in contrast to insignificant 
increased percentage of peripheral blood lymphocyte and 
undetectable MAGE3 specific T lymphocyte response, 
nor Th neither Tc induction of NK cell functions boosted 
in these patients.22 Table 1 lists some of the EXOs-based 
clinical trials conducted for diagnosis and/or therapy of 
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various malignancies.
It should be pinpointed that an effective tumor specific 
immune response within TME needs activation of both 
innate and adaptive immune systems through cellular 
(i.e., induction of natural killer (NK) cells, cytotoxic 
CD8+T cells and gamma delta T cells) and humoral such 
as antibody-dependent cellular cytotoxicity (ADCC) 
immune responses.13 However, the penetration of whole 
monoclonal antibodies (mAbs) into TME seems to be 
largely size-dependent in large part due to high oncotic 
pressure within TME, and often a population of cancer cells 
in the core of solid tumors appears to remain untouched 
that can be the main cause of disease relapse. To overcome 
these anomalous pathophysiologic traits of solid tumors, 
novel cancer therapy strategies have been implemented 
including multifunctional nanomedicines,23-39 
multispecific antibody (Ab) scaffolds,40-42 and various 
vaccination strategies such as edible vaccines.43 It should 
be stated that the selection of effective mAbs for cancer 
immunotherapy appears to be very laborious and 
sophisticated,44-46 while nanocarriers used in formulation 
of nanomedicines may induce inevitable toxic impacts 
nonspecifically.47-53 
Final remarks 
It appears that EXOs, TEXOs (small and large oncosomes) 
and DEXOs are important cellular micro-/nano-
machineries that are involved in many cellular functions. 
Based on the cell origin, in malignancies, these EVs convey 
various messages to promote or to inhibit antitumor 
responses. Despite plethora of investigations on various 
EVs, it seems we still need to fully decode the main 
messages of these silently whispering vesicles and examine 
their potentials in diagnosis and treatment of diseases (in 
particular malignancies) in which the involved cells use 
such intricate bio-machineries for their communications. 
The conducted studies together with the growing body 
of evidence indicate that EXOs provide great potentials 
as a novel nanoscale cellular machineries for various 
diagnostic and therapeutic purposes. However, there exist 
some striking questions to be addressed. What if these 
EVs convey signals to suppress the immunosurveillance 
or danger signals to make TME much more permissive? 
Is it likely that they shuttle danger signals to neighboring 
cells/tissue? Do the malignant cells use such capacity 
for the migration and hence colonization into the 
neighboring cells/tissue? What are the main roles of lipid 
rafts , membranous caveolae and clathrin coated-pitsd 
in this process? Taken all, in the best scenario, we may 
capitalize on these cell-free vaccination system. And, if we 
exploit these paramount and worth pursuing nanoshuttles 
for cancer immunotherapy and vaccination, which 
issues need to be considered to improve the exosomal 
immunogenicity? To the best of our knowledge, these EVs 
need to be optimized in terms of (a) the antigen-loading 
efficiency, (b) the compositions, morphology and sizes, (c) 
the in vivo trafficking, and finally (d) the biological fates 
and impacts in the target cells.
Table 1. List of the exosome-based clinical trials conducted for diagnosis and/or therapy of different malignancies
Trial ID: Description Cancer type Intervention/Experiment Sponsor
NCT01779583: Circulating Exosomes As Potential Prognostic 
And Predictive Biomarkers In Advanced Gastric Cancer Patients 
("EXO-PPP Study")
Gastric Cancer Molecular profile in 
tumor derived exosomes
Hospital Miguel 
Servet
NCT02393703: Interrogation of Exosome-mediated 
Intercellular Signaling in Patients With Pancreatic Cancer
Pancreatic Cancer Exosomes purification for 
downstream applications 
(e.g., proteomics and RNA 
sequencing)
Memorial Sloan 
Kettering Cancer 
Center
NCT01668849: Edible Plant Exosome Ability to Prevent Oral 
Mucositis Associated With Chemoradiation Treatment of Head 
and Neck Cancer
Head and Neck Cancer; 
Oral Mucositis
Dietary supplement: 
grape extract
James Graham Brown 
Cancer Center
NCT02147418: Exosome Testing as a Screening Modality for 
Human Papillomavirus-Positive Oropharyngeal Squamous Cell 
Carcinoma
Oropharyngeal Cancer Exosome protein 
signature outcome 
measure
New Mexico Cancer 
Care Alliance
NCT01294072: Study Investigating the Ability of Plant 
Exosomes to Deliver Curcumin to Normal and Colon Cancer 
Tissue
Colon Cancer Dietary supplement: 
curcumin conjugated with 
plant exosomes
James Graham Brown 
Cancer Center
NCT02071719: Prediction of Response to Kinase Inhibitors 
Based on Protein Phosphorylation Profiles in Tumor Tissue 
From Advanced Renal Cell Cancer Patients
Renal Cell Cancer Tumor exosomes from 
urine and serum
VU University 
Medical Center
NCT02310451: Study of Molecular Mechanisms Implicated in 
the Pathogenesis of Melanoma
Metastatic Melanoma Blood test Centre Hospitalier 
Universitaire de Nice
NCT02464930: Evaluation of MicroRNA Expression in Blood 
and Cytology for Detecting Barrett's Esophagus and Associated 
Neoplasia
Barrett's Esophagus;   
Gastroesophageal 
Reflux;   Esophageal 
Adenocarcinoma
Sensitivity and specificity 
of tissue and serum 
microRNA expression
Midwest Biomedical 
Research Foundation
NCT01550523: Pilot Immunotherapy Trial for Recurrent 
Malignant Gliomas
Malignant Glioma of 
Brain
IGF-1R/AS ODN Thomas Jefferson 
University
Data were obtained from clinicaltrials.gov website. All clinical trials listed were in recruiting phase. 
Cancer immunotherapy and vaccination: impacts of exosomes
BioImpacts, 2015, 5(3), 117-122 121
 Acknowledgments
Authors like to acknowledge the “Hope Pharmaceutical 
Technology LLC”  for the support.
 
Ethical issues
There is none to be disclosed.
Competing interests
No competing interests to be declared.
References
1. Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer 
G. The anticancer immune response: indispensable for therapeutic 
success? J Clin Invest 2008; 118: 1991-2001. doi:10.1172/JCI35180
2. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 
57-70. 
3. Zitvogel L, Tesniere A, Kroemer G. Cancer despite 
immunosurveillance: immunoselection and immunosubversion. 
Nat Rev Immunol 2006; 6: 715-27. doi:10.1038/nri1936
4. Omidi Y, Barar J. Targeting tumor microenvironment: crossing 
tumor interstitial fluid by multifunctional nanomedicines. 
Bioimpacts 2014; 4: 55-67. doi:10.5681/bi.2014.021
5. Barar J, Omidi Y. Dysregulated pH in Tumor Microenvironment 
Checkmates Cancer Therapy. Bioimpacts 2013; 3: 149-62. 
doi:10.5681/bi.2013.036
6. Poschke I, Mougiakakos D, Kiessling R. Camouflage and sabotage: 
tumor escape from the immune system. Cancer Immunol 
Immunother 2011; 60: 1161-71. doi:10.1007/s00262-011-1012-8
7. Gilmore AP. Anoikis. Cell Death Differ 2005; 12 Suppl 2: 1473-7. 
doi:10.1038/sj.cdd.4401723
8. Liotta LA, Kohn E. Anoikis: cancer and the homeless cell. Nature 
2004; 430: 973-4. doi:10.1038/430973a
9. Hao S, Moyana T, Xiang J. Review: cancer immunotherapy by 
exosome-based vaccines. Cancer Biother Radiopharm 2007; 22: 
692-703. doi:10.1089/cbr.2007.368-R
10. Schorey JS, Bhatnagar S. Exosome function: from tumor 
immunology to pathogen biology. Traffic 2008; 9: 871-81. 
doi:10.1111/j.1600-0854.2008.00734.x
11. Omidi Y, Gumbleton M. Biological membranes and barriers. In: 
Mahato, RI (ed). Biomaterials for Delivery and Targeting of Proteins 
Nucleic Acids. New York: CRC Press; 2005. p. 232-74.
12. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the 
confusion between extracellular vesicles. Trends Cell Biol 2015; 25: 
364-72. doi:10.1016/j.tcb.2015.01.004
13. Gehrmann U, Naslund TI, Hiltbrunner S, Larssen P, Gabrielsson 
S. Harnessing the exosome-induced immune response for cancer 
immunotherapy. Semin Cancer Biol 2014; 28: 58-67. doi:10.1016/j.
semcancer.2014.05.003
14. Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived 
exosomes stimulate stronger CD8+ CTL responses and antitumor 
immunity than tumor cell-derived exosomes. Cellular & Molecular 
Immunology 2006; 3: 205-11. 
15. Minciacchi VR, You S, Spinelli C, Morley S, Zandian M, Aspuria 
PJ, et al. Large oncosomes contain distinct protein cargo and 
represent a separate functional class of tumor-derived extracellular 
vesicles. Oncotarget 2015; 6: 11327-41. 
16. Di Vizio D, Morello M, Dudley AC, Schow PW, Adam RM, Morley 
S, et al. Large oncosomes in human prostate cancer tissues and in 
the circulation of mice with metastatic disease. Am J Pathol 2012; 
181: 1573-84. doi:10.1016/j.ajpath.2012.07.030
17. Gu X, Erb U, Buchler MW, Zoller M. Improved vaccine efficacy of 
tumor exosome compared to tumor lysate loaded dendritic cells in 
mice. Int J Cancer 2015; 136: E74-84. doi:10.1002/ijc.29100
18. Tran TH, Mattheolabakis G, Aldawsari H, Amiji M. Exosomes 
as nanocarriers for immunotherapy of cancer and inflammatory 
diseases. Clin Immunol 2015. doi:10.1016/j.clim.2015.03.021
19. Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, et al. 
Immune responses in patients with esophageal cancer treated with 
SART1 peptide-pulsed dendritic cell vaccine. Int J Oncol 2015; 46: 
1699-709. doi:10.3892/ijo.2015.2846
20. Naslund TI, Gehrmann U, Gabrielsson S. Cancer immunotherapy 
with exosomes requires B-cell activation. Oncoimmunology 2013; 
2: e24533. doi:10.4161/onci.24533
21. Temchura VV, Tenbusch M, Nchinda G, Nabi G, Tippler B, 
Zelenyuk M, et al. Enhancement of immunostimulatory properties 
of exosomal vaccines by incorporation of fusion-competent G 
protein of vesicular stomatitis virus. Vaccine 2008; 26: 3662-72. 
doi:10.1016/j.vaccine.2008.04.069
22. Escudier B, Dorval T, Chaput N, Andre F, Caby MP, Novault S, et 
al. Vaccination of metastatic melanoma patients with autologous 
dendritic cell (DC) derived-exosomes: results of thefirst phase I 
clinical trial. J Transl Med 2005; 3: 10. doi:10.1186/1479-5876-3-10
23. Barar J, Kafil V, Majd MH, Barzegari A, Khani S, Johari-Ahar 
M, et al. Multifunctional mitoxantrone-conjugated magnetic 
nanosystem for targeted therapy of folate receptor-overexpressing 
malignant cells. J Nanobiotechnol 2015; 13: 26. doi:10.1186/s12951-
015-0083-7
24. Matthaiou EI, Barar J, Sandaltzopoulos R, Li C, Coukos G, Omidi 
Y. Shikonin-loaded antibody-armed nanoparticles for targeted 
therapy of ovarian cancer. Int J Nanomedicine 2014; 9: 1855-70. 
doi:10.2147/IJN.S51880
25. Mashinchian O, Johari-Ahar M, Ghaemi B, Rashidi M, Barar J, 
Omidi Y. Impacts of quantum dots in molecular detection and 
bioimaging of cancer. Bioimpacts 2014; 4: 149-66. doi:10.15171/
bi.2014.008
26. Barar J, Omidi Y. Surface modified multifunctional nanomedicines 
for simultaneous imaging and therapy of cancer. Bioimpacts 2014; 
4: 3-14. doi:10.5681/bi.2014.011
27. Najar AG, Pashaei-Asl R, Omidi Y, Farajnia S, Nourazarian AR. 
EGFR antisense oligonucleotides encapsulated with nanoparticles 
decrease EGFR, MAPK1 and STAT5 expression in a human colon 
What is current knowledge?
√ Extracellular vesicles (exosomes) are important cellular 
micro-/nano-machineries that convey biological information.
√ Cancer-derived exosomes can favor the progression and 
development of cancer.
√ Dentric cells-derived exosomes may act against cancer 
progression and development. 
What is new here?
√ The information of exosomes must be decoded in different 
cancers and patients to be used for personalized diagnosis 
and therapy. 
√ Dentric cells-derived exosomes need to be carefully 
designed for cancer immunotherapy and vaccination. 
√ For achievement of greater immunotherapy and 
vaccination, the antigen-loading efficiency of exosomes 
must be improved.
√ The compositions, morphology and sizes of exosomes 
may affect their biological impacts.
√ In vivo trafficking and bio-degradation of exosomes must 
be fully clarified. 
Prospective Highlights
Rafi and Omidi
BioImpacts, 2015, 5(3), 117-122122
cancer cell line. Asian Pac J Cancer Prev 2013; 14: 495-8. 
28. Heidari Majd M, Barar J, Asgari D, Valizadeh H, Rashidi MR, 
Kafil V, et al. Targeted fluoromagnetic nanoparticles for imaging 
of breast cancer mcf-7 cells. Adv Pharm Bull 2013; 3: 189-95. 
doi:10.5681/apb.2013.031
29. Heidari Majd M, Asgari D, Barar J, Valizadeh H, Kafil V, Coukos 
G, et al. Specific targeting of cancer cells by multifunctional 
mitoxantrone-conjugated magnetic nanoparticles. J Drug Target 
2013; 21: 328-40. doi:10.3109/1061186X.2012.750325
30. Heidari Majd M, Asgari D, Barar J, Valizadeh H, Kafil V, Abadpour 
A, et al. Tamoxifen loaded folic acid armed PEGylated magnetic 
nanoparticles for targeted imaging and therapy of cancer. 
Colloids Surf B Biointerfaces 2013; 106: 117-25. doi:10.1016/j.
colsurfb.2013.01.051
31. Barar J, Omidi Y. Targeted Gene Therapy of Cancer: Second 
Amendment toward Holistic Therapy. Bioimpacts 2013; 3: 49-51. 
doi:10.5681/bi.2013.014
32. Nourazarian AR, Pashaei-Asl R, Omidi Y, Najar AG. c-Src 
antisense complexed with PAMAM denderimes decreases of c-Src 
expression and EGFR-dependent downstream genes in the human 
HT-29 colon cancer cell line. Asian Pac J Cancer Prev 2012; 13: 
2235-40. 
33. Nourazarian AR, Najar AG, Farajnia S, Khosroushahi AY, 
Pashaei-Asl R, Omidi Y. Combined EGFR and c-Src antisense 
oligodeoxynucleotides encapsulated with PAMAM Denderimers 
inhibit HT-29 colon cancer cell proliferation. Asian Pac J Cancer 
Prev 2012; 13: 4751-6. 
34. Khosroushahi AY, Naderi-Manesh H, Yeganeh H, Barar J, Omidi 
Y. Novel water-soluble polyurethane nanomicelles for cancer 
chemotherapy: physicochemical characterization and cellular 
activities. J Nanobiotechnology 2012; 10: 2. doi:10.1186/1477-3155-
10-2
35. Barar J, Omidi Y. Translational Approaches towards Cancer 
Gene Therapy: Hurdles and Hopes. Bioimpacts 2012; 2: 127-43. 
doi:10.5681/bi.2012.025
36. Omidi Y. Smart multifunctional theranostics: simultaneous 
diagnosis and therapy of cancer. Bioimpacts 2011; 1: 145-7. 
doi:10.5681/bi.2011.019
37. Omidi Y. CNT Nanobombs for Specific Eradication of Cancer 
Cells: A New Concept in Cancer Theranostics. Bioimpacts 2011; 1: 
199-201. doi:10.5681/bi.2011.028
38. Rezaiemanesh A, Majidi J, Baradaran B, Movasaghpour A, 
Nakhlband A, Barar J, et al. Impacts of anti-EGFR monoclonal 
antibody in prostate cancer PC3 cells. Hum Antibodies 2010; 19: 
63-70. doi:10.3233/HAB-2010-0229
39. Nakhlband A, Barar J, Bidmeshkipour A, Heidari HR, Omidi Y. 
Bioimpacts of anti epidermal growth factor receptor antisense 
complexed with polyamidoamine dendrimers in human lung 
epithelial adenocarcinoma cells. J Biomed Nanotechnol 2010; 6: 
360-9. 
40. Caravella J, Lugovskoy A. Design of next-generation protein 
therapeutics. Curr Opin Chem Biol 2010; 14: 520-8. doi:10.1016/j.
cbpa.2010.06.175
41. Lofblom J, Frejd FY, Stahl S. Non-immunoglobulin based protein 
scaffolds. Curr Opin Biotechnol 2011; 22: 843-8. doi:10.1016/j.
copbio.2011.06.002
42. Weidle UH, Auer J, Brinkmann U, Georges G, Tiefenthaler G. The 
emerging role of new protein scaffold-based agents for treatment of 
cancer. Cancer Genomics Proteomics 2013; 10: 155-68. 
43. Barzegari A, Saeedi N, Zarredar H, Barar J, Omidi Y. The search for 
a promising cell factory system for production of edible vaccine. 
Hum Vaccin Immunother 2014; 10: 2497-502. doi:10.4161/hv.29032
44. Zhao A, Tohidkia MR, Siegel DL, Coukos G, Omidi Y. Phage 
antibody display libraries: a powerful antibody discovery platform 
for immunotherapy. Crit Rev Biotechnol 2014; 1-14. doi:10.3109/0
7388551.2014.958978
45. Tohidkia MR, Barar J, Asadi F, Omidi Y. Molecular considerations 
for development of phage antibody libraries. J Drug Target 2012; 
20: 195-208. doi:10.3109/1061186X.2011.611517
46. Majidi J, Barar J, Baradaran B, Abdolalizadeh J, Omidi Y. Target 
therapy of cancer: implementation of monoclonal antibodies and 
nanobodies. Hum Antibodies 2009; 18: 81-100. doi:10.3233/HAB-
2009-0204
47. Barar J, Omidi Y. Intrinsic bio-signature of gene delivery 
nanocarriers may impair gene therapy goals. Bioimpacts 2013; 3: 
105-9. doi:10.5681/bi.2013.028
48. Kafil V, Omidi Y. Cytotoxic impacts of linear and branched 
polyethylenimine nanostructures in a431 cells. Bioimpacts 2011; 1: 
23-30. doi:10.5681/bi.2011.004
49. Omidi Y, Barar J. Induction of human alveolar epithelial cell growth 
factor receptors by dendrimeric nanostructures. Int J Toxicol 2009; 
28: 113-22. doi:10.1177/1091581809335177
50. Ahmadian S, Barar J, Saei AA, Fakhree MA, Omidi Y. Cellular 
toxicity of nanogenomedicine in MCF-7 cell line: MTT assay. J Vis 
Exp 2009. doi:10.3791/1191
51. Omidi Y, Barar J, Heidari HR, Ahmadian S, Yazdi HA, Akhtar 
S. Microarray analysis of the toxicogenomics and the genotoxic 
potential of a cationic lipid-based gene delivery nanosystem in 
human alveolar epithelial a549 cells. Toxicol Mech Methods 2008; 
18: 369-78. doi:10.1080/15376510801891286
52. Omidi Y, Barar J, Akhtar S. Toxicogenomics of cationic lipid-based 
vectors for gene therapy: impact of microarray technology. Curr 
Drug Deliv 2005; 2: 429-41. 
53. Omidi Y, Hollins AJ, Benboubetra M, Drayton R, Benter IF, 
Akhtar S. Toxicogenomics of non-viral vectors for gene therapy: 
a microarray study of lipofectin- and oligofectamine-induced gene 
expression changes in human epithelial cells. J Drug Target 2003; 
11: 311-23. doi:10.1080/10611860310001636908
